Nuveen California Select Tax-Free Income Portfolio
Change company Symbol lookup
Select an option...
XNXCX Nuveen California Select Tax-Free Income Portfolio
AMGN Amgen Inc
AMSC American Superconductor Corp
CVBF CVB Financial Corp
PHG Koninklijke Philips NV
IVR Invesco Mortgage Capital Inc
CORE Core-Mark Holding Company Inc
ATMH All Things Mobile Analytic Inc
INCT Incapta Inc
BML-J Bank of America Corp
Go

Company profile

Nuveen California Select Tax-Free Income Portfolio (the Fund) is a diversified closed-end management investment company. The Fund's investment objective is to provide stable dividends exempt from both regular federal income tax and California personal income tax, consistent with preservation of capital. The Fund invests in municipal securities that are exempt from federal and California state income taxes. The Fund invests approximately 80% of its managed assets in securities rated, at the time of investment, investment grade (Baa/BBB or better by S&P, Moody's, or Fitch) or, if they are unrated, are judged by the manager to be of comparable quality. The Fund may invest over 20% of its managed assets in municipal securities rated below investment quality or judged by the manager to be of comparable quality, of which approximately 10% of its managed assets may be rated below B-/B3 or of comparable quality. The Fund's investment advisor is Nuveen Fund Advisors, LLC.

Closing Price
$15.96
Day's Change
0.01 (0.06%)
Bid
--
Ask
--
B/A Size
--
Day's High
15.96
Day's Low
15.96
Volume
0

UPCOMING DEADLINE Pawar Law Group Announces a Securities Class Action Lawsuit Against Reata Pharmaceuticals, Inc.- RETA

5:00 pm ET November 27, 2020 (Globe Newswire) Print

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) from October 15, 2019 through August 7, 2020, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Reata Pharmaceuticals, Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the MOXIe Part 2 study results were insufficient to support a single study marketing approval of omaveloxolone for the treatment of Friedreich's ataxia ("FA") in the U.S. without additional evidence; (2) as a result, it was foreseeably likely that the FDA would not accept marketing approval of omaveloxolone for the treatment of FA in the U.S. based on the MOXIe Part 2 study results; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff, you must move the Court no later than December 14, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

-------------------------------

Contact:

Vik Pawar, Esq.

Pawar Law Group

20 Vesey Street, Suite 1410

New York, NY 10007

Tel: (917) 261-2277

Fax: (212) 571-0938

info@pawarlawgroup.com

https://ml.globenewswire.com/media/9201a0e3-e798-4f48-8976-709fee459fa2/small/pawar-law-group-logo-gold-png.png

https://ml.globenewswire.com/media/9201a0e3-e798-4f48-8976-709fee459fa2/small/pawar-law-group-logo-gold-png.png

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.